NervGen Pharma Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which are exercisable at a price of $1.75 per share and 100,000 of which are exercisable at $2.00 per share for a period of three years and that vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company's stock option plan.

About NervGen
NervGen is restoring life's potential by creating innovative solutions for the treatment of nervous system injury due to trauma or disease as a result of underlying inflammation and/or neurodegeneration. The Company is initially developing drugs for the treatment of multiple sclerosis, spinal cord injury and Alzheimer's disease.

For further information, please contact:

Huitt Tracey, Corporate Communications
[email protected]
c: 604.362.6209

Nancy Thompson, Vorticom Public Relations
[email protected]
212.532.2208

Follow NervGen on Twitter (@NervgenP) and LinkedIn (NervGen Pharma Corp.) for the latest news on the Company.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/90548

You May Also Be Interested In

• FCLGO Launches Amazon Fulfillment Center Locations Routing Service to Eliminate FBA Compliance Rejections for Cross-Border Sellers
• Julien Frascadore Named Team Canada 2026 Closing Ceremonies Flagbearer
• The Shift from Fast Fashion to Intentional Luxury Purchasing: What It Means for Brands